NYMC Faculty Publications

In Vitro Cytotoxicity of Ranpirnase (Onconase) in Combination With Components of R-CHOP Regimen Against Diffuse Large B Cell Lymphoma (DLBCL) Cell Line

Author Type(s)

Faculty

DOI

10.5604/17322693.1078386

Journal Title

Postepy Higieny i Medycyny Doswiadczalnej

First Page

1166

Last Page

1172

Document Type

Article

Publication Date

12-2-2013

Department

Medicine

Abstract

Ranpirnase (onconase; ONC) is an endoribonuclease obtained from the frog Rana pipiens. This enzyme exhibits anticancer properties mediated by degradation of cellular RNA and induction of apoptosis. In this study we assessed cytotoxicity of ONC in combination with currently used anticancer drugs on a human diffuse large B-cell lymphoma (DLBCL)-derived cell line (Toledo). Cytotoxic activity was measured by the exclusion of propidium iodide assay while apoptosis was assessed using the annexin-V binding method. Additionally, flow cytometry was used to assess the decline of mitochondrial potential and to determine activation of caspases 3, 8 and 9. It was observed that in vitro treatment with ONC in combination with rituximab, mafosfamide, vincristine, doxorubicin, and dexamethasone (drugs corresponding with elements of R-CHOP regimen) resulted in increased cytotoxicity. As a result ONC showed marked cytotoxicity against Toledo cells. Importantly, in combination of ONC with drugs imitating the R-CHOP regimen, this effect was significantly intensified. The main mechanism responsible for this event was induction of apoptosis along a mitochondrial dependent pathway. In conclusion, these data indicate that further preclinical and eventually clinical studies assessing activity of ONC+R-CHOP treatment are warranted.

Link to Full Text

Share

COinS